SBIR Phase I: Catechol Linker Oligosaccharide Combinations for Antimicrobial Surfaces

SBIR 第一阶段：用于抗菌表面的儿茶酚连接寡糖组合

• 批准号: 2143961
• 负责人: Randell Clevenger
• 金额: $ 25.59万
• 依托单位: MOLECULAR SURFACE TECHNOLOGIES LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2143961&HistoricalAwards=false
• 关键词: SBIR; Phase; Catechol; Linker; Oligosaccharide

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase 1 project is a decrease in the devastating effects of deep implant-related infections. The technology could result in advances to the clinical health and welfare of the American public by improving clinical outcomes and decreasing morbidity and mortality. The technology addressed by this project may protect surgical implants, such as joint replacements and spinal fusion systems from bacterial colonization and developing infections. This technology could significantly reduce the greater than $3 billion cost to the US healthcare system from implant related infections. This antimicrobial technology could be used beyond medical applications for such things as food packaging to decrease foodborne diseases and more than double shelf-life of certain food products. Additionally, the linker technology developed through this project may be used to create super slick or self-cleaning surfaces with applications in the aerospace and marine industries resulting in increased fuel efficiency and performance.The project aims to develop a homogeneous, covalently bound, linker molecule attached to medical implant material (titanium alloy) upon which a quaternary ammonium-modified oligosaccharide will be subsequently attached. Oligosaccharides are known to be biocompatible and quaternized oligosaccharides are highly potent antimicrobials. A treated medical implant could possess a powerfully antimicrobial surface so that, during surgery, any bacteria that encounter the surface will be killed. In this way, it is hoped that the avascular surface of the implant will not serve as a site for biofilm formation and growth and thus, reduce the incidence of perioperative infections. The key to any successful surface modification is the quality of the chemical attachment of linkers and active molecules to that surface. Polyphenols and catechols such as dopamine are ideal candidates for investigation as these molecules are generally known for their facility in forming thin films onto a wide variety of surfaces. Using dopamine as a model system, catechol analogs will be electrochemically attached, and the resulting thin films analyzed for attachment, thickness, ease of further modification, and morphology. Atomic Force Microscopy (AFM), UV/Visible spectroscopy, soak/stress protocols and microbiology will be used to gauge the success or failure of a thin film plus oligosaccharide combination.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这一小型企业创新研究（SBIR）第1阶段项目的更广泛/商业影响是减少了深部植入物相关感染的破坏性影响。 该技术可以通过改善临床结果和降低发病率和死亡率来促进美国公众的临床健康和福利。该项目所涉及的技术可以保护外科植入物，如关节置换和脊柱融合系统免受细菌定植和感染。这项技术可以显著降低美国医疗保健系统因植入物相关感染而产生的30多亿美元成本。这种抗菌技术可以用于食品包装等医疗应用之外，以减少食源性疾病，并使某些食品的保质期延长一倍以上。此外，通过该项目开发的连接剂技术可用于制造超光滑或自清洁表面，应用于航空航天和海洋工业，从而提高燃料效率和性能。该项目旨在开发一种连接到医疗植入材料（钛合金）上的均质共价结合连接剂分子，随后将在其上连接季铵改性寡糖。已知寡糖具有生物相容性，季铵化寡糖是高效抗菌剂。经过处理的医疗植入物可以拥有强大的抗菌表面，以便在手术过程中，任何遇到表面的细菌都将被杀死。通过这种方式，希望植入物的无血管表面不会成为生物膜形成和生长的部位，从而降低围手术期感染的发生率。任何成功的表面改性的关键是连接体和活性分子与该表面的化学连接的质量。多酚类和儿茶酚类如多巴胺是理想的研究候选物，因为这些分子通常以其在各种表面上形成薄膜的能力而闻名。使用多巴胺作为模型系统，儿茶酚类似物将电化学连接，并分析所得薄膜的附着，厚度，进一步修饰的容易性和形态。原子力显微镜（AFM）、紫外/可见光谱、浸泡/压力协议和微生物学将用于衡量薄膜加寡糖组合的成功或失败。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。